Click here for slides on this topic


Pioglitazone and glimepiride

Combination sulfonylurea and thiazolidinedione (TZD) oral medication for glycemic control in type 2 diabetes.
The following content matched the glossary term: Pioglitazone and glimepiride

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin

Top

Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-483. A recent position statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) cites metformin as the optimal first-line drug for diabetes treatment. However, the statement acknowledges that limited data exist regarding treatments to be used beyond metformin.

ADA/European Association for the Study of Diabetes (EASD) Position Statement on Hyperglycemia Management in Type 2 Diabetes

Top

Joint position statement from ADA/EASD with clinical practice recommendations for managing hyperglycemia in type 2 diabetes

Clinical Insights in Diabetes Newsletter Archive

Top

Clinical Insights® in Diabetes Newsletter Archive

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting

Top

Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011;34(6):1369-71. OBJECTIVE To analyze the association between pioglitazone use and bladder cancer through a spontaneous adverse event reporting system for medications.

The role of pioglitazone in modifying the atherogenic lipoprotein profile

Top

Hanefeld M. The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes, Obesity and Metabolism. 2009;11(8):742-756. Pioglitazone, a thiazolidinedione, has established efficacy in improving glycaemic control in patients with type 2 diabetes. Pioglitazone also improves components of the mixed dyslipidaemia profile common in these patients, as typified by raised levels of plasma triglycerides, low levels of HDL cholesterol (HDL-C) and a raised proportion of LDL cholesterol (LDL-C) occurring as the small dense subfraction.

Pioglitazone vs glimepiride: differential effects on vascular endothelial function in patients with type 2 diabetes

Top

Papathanassiou K, Naka KK, Kazakos N, et al. Pioglitazone vs glimepiride: differential effects on vascular endothelial function in patients with type 2 diabetes. Atherosclerosis. 2008 Dec 6. [Epub ahead of print]. The aim of this study was to compare the effect of glimepiride and pioglitazone on endothelial function in patients with type 2 diabetes already on metformin.

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes

Top

Nissen SE, Nicholls SJ, Wolski K, et al; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561-73. No antidiabetic regimen has demonstrated the ability to reduce progression of coronary atherosclerosis. Commonly used oral glucose-lowering agents include sulfonylureas, which are insulin secretagogues, and thiazolidinediones, which are insulin sensitizers.

1 2 Next 

Slide Library Results

Search Results for: Pioglitazone and glimepiride Slides Found: 0